Corcept Looks To End Teva's Mifepristone Antitrust Case
Corcept Therapeutics told a California federal court there's no evidence that it blocked generic competition for its cortisol disorder treatment Korlym, urging the court to toss an antitrust case from Teva...To view the full article, register now.
Already a subscriber? Click here to view full article